A recent study demonstrated the efficacy of EGFR tyrosine kinase inhibitors, as well as the associated molecular mechanisms, on diabetes control and insulin action in high-fat-diet-fed mice, and suggested that EGFR and/or its signaling pathway may have a role in insulin resistance in obesity and diabetes; those results support our own regarding the possible role of EGFR tyrosine kinase inhibitors in metabolic disorders [26]. This evidence concerns the gene INS and Insulin resistance.